Prosthetic Joint Infections Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

Description

The global prosthetic joint infection treatment market is expected to grow significantly over the next decade.The market is projected to reach $110.66 million in 2024 and $156.82 million in 2031, growing at a CAGR of 5.10%. Prosthetic joint infections (PJIs) require effective therapeutic strategies such as debridement, antibiotics, and irrigation with implant retention (DAIR) therapy due to their complex nature. These infections can be caused by factors like surgical site contamination, hematogenous spread of bacteria, or direct introduction during implant surgery. Bacteria form biofilms on the implant surface, making them resistant to immune responses and antibiotics.

DAIR therapy is crucial because it offers simplicity, shorter recovery times, and improved quality of life. The success of this treatment depends on factors like pathogen type, antibiotic sensitivity, and early intervention. This highlights the need for innovative approaches in managing PJIs.

Key Factors Driving Demand

Glycopeptides: Glycopeptides have a significant market share and are essential in managing severe bacterial infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci. These antibiotics, such as vancomycin and teicoplanin, are often used as first-line therapies or in combination with other antibiotics due to their potent bactericidal effects.

Prosthetic Joint Infection Solutions: These solutions hold a notable share of the global surgical site infection control market. Understanding biofilm formation is critical to developing targeted therapies, combination therapies, and preventive strategies. Combining antibiotics, antimicrobial agents, and biofilm-disrupting agents can increase treatment efficacy.

Increasing Procedures and Costs

PJIs are becoming a growing concern in orthopedics, particularly with the rise in total hip and knee arthroplasty procedures. PJIs lead to higher hospital readmissions, patient mortality, and substantial treatment costs, often up to four times the cost of primary implantation. Risk factors include revision arthroscopy, prior infection, smoking, obesity, rheumatoid arthritis, cancer, immunosuppression, and diabetes mellitus.

Diagnosis and Treatment Challenges

PJI diagnosis is challenging due to the virulence of pathogenic bacteria and varying patient responses. Treatment typically involves multiple surgical procedures and prolonged medical therapy, resulting in significant financial burdens. Gram-negative microbes also pose challenges, but adherence to basic principles like short symptom duration and anti-biofilm antibiotic treatment can make DAIR therapy successful.

Influencing Demand Growth

DAIR Procedures and Multidisciplinary Collaboration: Demand for PJI treatments is driven by several key factors, emphasizing effective therapeutic strategies. DAIR procedures are gaining attention due to their simplicity, shorter recovery times, and reduced physiological damage. Successful DAIR procedures result in functional outcomes and improved quality of life comparable to uninfected cases. Factors influencing the success of implant retention surgery DAIR include the method, antibiotic regimen, host health, and pathogen type.

Biofilms and Innovative Treatments: Biofilms are organized microbial communities with phenotypic variations, fostering bacteria growth resistant to the host immune system and drugs. These biofilms can form on the implanted joint prosthesis, leading to persistent infections. Innovative and effective treatment strategies are crucial to combat prosthetic joint infections caused by biofilm-forming bacteria. Early intervention and anti-biofilm antibiotic treatment are essential for successful outcomes.

Main Challenges

Limited Success of DAIR Therapy and Antibiotic Resistance: DAIR procedures, while simpler and less physiologically harmful, often have limited success. Patients who experience failed DAIR often require additional surgeries, leading to increased morbidity and costs. The success of DAIR can be affected by factors such as the infecting microorganism's sensitivity to antibiotics. For instance, MRSA infections often yield poor DAIR outcomes. Antibiotic resistance, particularly among gram-negative microbes, further complicates treatment.

Biofilm Paradigm: The microbial biofilm paradigm involves organized microbial communities with drug-resistant properties. Biofilms generate matrices that support bacteria growth, resisting immune response and treatment. Variables like the method, antibiotic regimen, host condition, and pathogen type affect DAIR outcomes. Exchange arthroplasty has a higher chance of success than debridement alone, although methicillin resistance has little effect on wound healing speed.

Country-wise Insights

United States: The U.S. holds a significant share of the global prosthetic joint infection treatment market. Growing demand for PJI treatment in the U.S. is linked to healthcare-associated infections (HCAIs) that develop during medical care. Simple measures such as hand hygiene can prevent HCAIs, reducing morbidity, mortality, and healthcare costs. Infection control efforts, including hand-washing initiatives, are vital in addressing the demand for effective PJI treatment.

India: India has a notable share of the global market, driven by the remarkable growth of its healthcare sector and medical tourism. The Indian healthcare industry offers competitive pricing, skilled medical professionals, high-quality care, and diverse treatments. Government initiatives further amplify India's appeal as a medical travel destination, attracting patients globally.

China: China also holds a significant share of the global market. Demand for PJI treatment in China is growing due to the expanding patient pool requiring artificial joint replacement procedures. PJIs pose a significant therapeutic challenge, leading to an increased socioeconomic burden on the Chinese healthcare system.

Category-wise Insights

Drug Utilization: Glycopeptides are widely used for PJI treatment, occupying a significant market share. These antibiotics are crucial in managing severe bacterial infections, particularly those caused by MRSA and coagulase-negative staphylococci. Their ability to target resistant strains and provide effective treatment makes them essential in addressing infections associated with prosthetic joint replacements.

Infection Type: Post-operative infections are prevalent and accounted for a large share of the market. These infections frequently need specialist care, such as antibiotics and, in severe situations, surgery to remove the infected implant. The complexity and severity of post-operative infections fuel the demand for innovative and effective treatment solutions.

Pathogen Type: Staphylococcus aureus is the most common pathogen, causing early infections due to its aggressive nature and ubiquity. This pathogen develops biofilms, making infections difficult to treat and recurring. Effective treatment options for Staphylococcus aureus and associated biofilm are critical, generating significant demand for specialist therapies.

Route of Administration: Intravenous administration is widely preferred due to its direct and rapid delivery of antibiotics into the bloodstream. This method ensures effective and targeted treatment, reaching the infection site directly. Intravenous administration allows for close monitoring and adjustment of the treatment regimen, contributing to better patient outcomes.

Competition Analysis

The prosthetic joint infection treatment industry is highly fragmented, with several competitors offering products and services locally. These businesses use strategies such as business expansion and innovation to meet patient demands and grow their customer base.

Recent Developments:

University of Buffalo researchers and Garwood Medical Devices collaborated to evaluate BioPrax, a device to prevent, control, and eliminate bacterial biofilm infections in orthopedic implants, receiving a Breakthrough Device designation from the FDA.
Peptilogics received FDA QIDP designation for its PLG0206 treatment for PJIs, potentially reducing inpatient costs significantly.

Key Companies Covered

Pfizer Inc.
Novartis AG
Mylan N.V.
Teva Pharmaceuticals
Merck & Co.
Eli Lilly & Company
AstraZeneca PLC
Lupin Limited
Dr. Reddys Laboratories
Aurobindo Pharma Ltd.
GSK PLC
Sun Pharmaceutical Industries Ltd.
Cipla Ltd.

Key Segments of Prosthetic Joint Infection Treatment Industry Research

By Drug:

Aminoglycosides
Glycopeptides
Rifamycin
Lincosamide
Penicillin
Other Antibiotics

By Infection:

Pre-operative Infection
Post-operative Infection

By Route of Administration:

Oral
Intravenous

By Pathogen:

Staphylococcus Aureus
Coagulase-negative Staphylococcus
Candida Species
Enterococcus Species
Other Pathogens

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa

1. Executive Summary

1.1. Global Prosthetic Joint Infections Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2024
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Prosthetic Joint Infections Treatment Market Outlook, 2019-2031

3.1. Global Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2019-2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Aminoglycosides
  - 3.1.1.2. Glycopeptides
  - 3.1.1.3. Rifamycin
  - 3.1.1.4. Lincosamide
  - 3.1.1.5. Penicillin
  - 3.1.1.6. Other Antibiotics
3.2. Global Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2019-2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Pre-operative Infection
  - 3.2.1.2. Post-operative Infection
3.3. Global Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2019-2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Oral
  - 3.3.1.2. Intravenous
3.4. Global Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2019-2031
- 3.4.1. Key Highlights
  - 3.4.1.1. Staphylococcus Aureus
  - 3.4.1.2. Coagulase-negative Staphylococcus
  - 3.4.1.3. Candida Species
  - 3.4.1.4. Enterococcus Species
  - 3.4.1.5. Others
3.5. Global Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2019-2031
- 3.5.1. Key Highlights
  - 3.5.1.1. Hospital Pharmacies
  - 3.5.1.2. Retail Pharmacies
  - 3.5.1.3. Drug Stores
  - 3.5.1.4. Online Sales
3.6. Global Prosthetic Joint Infections Treatment Market Outlook, by Region, Value (US$ Mn), 2019-2031
- 3.6.1. Key Highlights
  - 3.6.1.1. North America
  - 3.6.1.2. Europe
  - 3.6.1.3. Asia Pacific
  - 3.6.1.4. Latin America
  - 3.6.1.5. Middle East & Africa

4. North America Prosthetic Joint Infections Treatment Market Outlook, 2019-2031

4.1. North America Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2019-2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Aminoglycosides
  - 4.1.1.2. Glycopeptides
  - 4.1.1.3. Rifamycin
  - 4.1.1.4. Lincosamide
  - 4.1.1.5. Penicillin
  - 4.1.1.6. Other Antibiotics
4.2. North America Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2019-2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Pre-operative Infection
  - 4.2.1.2. Post-operative Infection
4.3. North America Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2019-2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Oral
  - 4.3.1.2. Intravenous
4.4. North America Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2019-2031
- 4.4.1. Key Highlights
  - 4.4.1.1. Staphylococcus Aureus
  - 4.4.1.2. Coagulase-negative Staphylococcus
  - 4.4.1.3. Candida Species
  - 4.4.1.4. Enterococcus Species
  - 4.4.1.5. Others
4.5. North America Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2019-2031
- 4.5.1. Key Highlights
  - 4.5.1.1. Hospital Pharmacies
  - 4.5.1.2. Retail Pharmacies
  - 4.5.1.3. Drug Stores
  - 4.5.1.4. Online Sales
4.6. North America Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2019-2031
- 4.6.1. Key Highlights
  - 4.6.1.1. U.S. Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 4.6.1.2. U.S. Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 4.6.1.3. U.S. Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 4.6.1.4. U.S. Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 4.6.1.5. U.S. Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 4.6.1.6. Canada Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 4.6.1.7. Canada Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 4.6.1.8. Canada Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 4.6.1.9. Canada Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 4.6.1.10. Canada Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
- 4.6.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Prosthetic Joint Infections Treatment Market Outlook, 2019-2031

5.1. Europe Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2019-2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Aminoglycosides
  - 5.1.1.2. Glycopeptides
  - 5.1.1.3. Rifamycin
  - 5.1.1.4. Lincosamide
  - 5.1.1.5. Penicillin
  - 5.1.1.6. Other Antibiotics
5.2. Europe Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2019-2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Pre-operative Infection
  - 5.2.1.2. Post-operative Infection
5.3. Europe Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2019-2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Oral
  - 5.3.1.2. Intravenous
5.4. Europe Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2019-2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Staphylococcus Aureus
  - 5.4.1.2. Coagulase-negative Staphylococcus
  - 5.4.1.3. Candida Species
  - 5.4.1.4. Enterococcus Species
  - 5.4.1.5. Others
5.5. Europe Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2019-2031
- 5.5.1. Key Highlights
  - 5.5.1.1. Hospital Pharmacies
  - 5.5.1.2. Retail Pharmacies
  - 5.5.1.3. Drug Stores
  - 5.5.1.4. Online Sales
5.6. Europe Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2019-2031
- 5.6.1. Key Highlights
  - 5.6.1.1. Germany Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 5.6.1.2. Germany Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 5.6.1.3. Germany Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 5.6.1.4. Germany Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 5.6.1.5. Germany Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 5.6.1.6. U.K. Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 5.6.1.7. U.K. Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 5.6.1.8. U.K. Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 5.6.1.9. U.K. Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 5.6.1.10. U.K. Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 5.6.1.11. France Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 5.6.1.12. France Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 5.6.1.13. France Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 5.6.1.14. France Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 5.6.1.15. France Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 5.6.1.16. Italy Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 5.6.1.17. Italy Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 5.6.1.18. Italy Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 5.6.1.19. Italy Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 5.6.1.20. Italy Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 5.6.1.21. Turkey Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 5.6.1.22. Turkey Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 5.6.1.23. Turkey Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 5.6.1.24. Turkey Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 5.6.1.25. Turkey Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 5.6.1.26. Russia Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 5.6.1.27. Russia Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 5.6.1.28. Russia Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 5.6.1.29. Russia Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 5.6.1.30. Russia Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 5.6.1.31. Rest of Europe Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 5.6.1.32. Rest of Europe Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 5.6.1.33. Rest of Europe Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 5.6.1.34. Rest of Europe Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 5.6.1.35. Rest of Europe Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
- 5.6.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, 2019-2031

6.1. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2019-2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Aminoglycosides
  - 6.1.1.2. Glycopeptides
  - 6.1.1.3. Rifamycin
  - 6.1.1.4. Lincosamide
  - 6.1.1.5. Penicillin
  - 6.1.1.6. Other Antibiotics
6.2. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2019-2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Pre-operative Infection
  - 6.2.1.2. Post-operative Infection
6.3. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2019-2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Oral
  - 6.3.1.2. Intravenous
6.4. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2019-2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Staphylococcus Aureus
  - 6.4.1.2. Coagulase-negative Staphylococcus
  - 6.4.1.3. Candida Species
  - 6.4.1.4. Enterococcus Species
  - 6.4.1.5. Others
6.5. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2019-2031
- 6.5.1. Key Highlights
  - 6.5.1.1. Hospital Pharmacies
  - 6.5.1.2. Retail Pharmacies
  - 6.5.1.3. Drug Stores
  - 6.5.1.4. Online Sales
6.6. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2019-2031
- 6.6.1. Key Highlights
  - 6.6.1.1. China Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 6.6.1.2. China Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 6.6.1.3. China Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 6.6.1.4. China Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 6.6.1.5. China Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 6.6.1.6. Japan Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 6.6.1.7. Japan Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 6.6.1.8. Japan Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 6.6.1.9. Japan Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 6.6.1.10. Japan Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 6.6.1.11. South Korea Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 6.6.1.12. South Korea Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 6.6.1.13. South Korea Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 6.6.1.14. South Korea Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 6.6.1.15. South Korea Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 6.6.1.16. India Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 6.6.1.17. India Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 6.6.1.18. India Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 6.6.1.19. India Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 6.6.1.20. India Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 6.6.1.21. Southeast Asia Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 6.6.1.22. Southeast Asia Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 6.6.1.23. Southeast Asia Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 6.6.1.24. Southeast Asia Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 6.6.1.25. Southeast Asia Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 6.6.1.26. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 6.6.1.27. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 6.6.1.28. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 6.6.1.29. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 6.6.1.30. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
- 6.6.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Prosthetic Joint Infections Treatment Market Outlook, 2019-2031

7.1. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2019-2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Aminoglycosides
  - 7.1.1.2. Glycopeptides
  - 7.1.1.3. Rifamycin
  - 7.1.1.4. Lincosamide
  - 7.1.1.5. Penicillin
  - 7.1.1.6. Other Antibiotics
7.2. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2019-2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Pre-operative Infection
  - 7.2.1.2. Post-operative Infection
7.3. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2019-2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Oral
  - 7.3.1.2. Intravenous
7.4. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2019-2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Staphylococcus Aureus
  - 7.4.1.2. Coagulase-negative Staphylococcus
  - 7.4.1.3. Candida Species
  - 7.4.1.4. Enterococcus Species
  - 7.4.1.5. Others
7.5. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2019-2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Hospital Pharmacies
  - 7.5.1.2. Retail Pharmacies
  - 7.5.1.3. Drug Stores
  - 7.5.1.4. Online Sales
7.6. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2019-2031
- 7.6.1. Key Highlights
  - 7.6.1.1. Brazil Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 7.6.1.2. Brazil Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 7.6.1.3. Brazil Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 7.6.1.4. Brazil Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 7.6.1.5. Brazil Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 7.6.1.6. Mexico Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 7.6.1.7. Mexico Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 7.6.1.8. Mexico Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 7.6.1.9. Mexico Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 7.6.1.10. Mexico Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 7.6.1.11. Argentina Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 7.6.1.12. Argentina Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 7.6.1.13. Argentina Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 7.6.1.14. Argentina Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 7.6.1.15. Argentina Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 7.6.1.16. Rest of Latin America Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 7.6.1.17. Rest of Latin America Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 7.6.1.18. Rest of Latin America Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 7.6.1.19. Rest of Latin America Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 7.6.1.20. Rest of Latin America Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
- 7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, 2019-2031

8.1. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2019-2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Aminoglycosides
  - 8.1.1.2. Glycopeptides
  - 8.1.1.3. Rifamycin
  - 8.1.1.4. Lincosamide
  - 8.1.1.5. Penicillin
  - 8.1.1.6. Other Antibiotics
8.2. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2019-2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Pre-operative Infection
  - 8.2.1.2. Post-operative Infection
8.3. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2019-2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Oral
  - 8.3.1.2. Intravenous
8.4. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2019-2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Staphylococcus Aureus
  - 8.4.1.2. Coagulase-negative Staphylococcus
  - 8.4.1.3. Candida Species
  - 8.4.1.4. Enterococcus Species
  - 8.4.1.5. Others
8.5. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2019-2031
- 8.5.1. Key Highlights
  - 8.5.1.1. Hospital Pharmacies
  - 8.5.1.2. Retail Pharmacies
  - 8.5.1.3. Drug Stores
  - 8.5.1.4. Online Sales
8.6. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2019-2031
- 8.6.1. Key Highlights
  - 8.6.1.1. GCC Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 8.6.1.2. GCC Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 8.6.1.3. GCC Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 8.6.1.4. GCC Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 8.6.1.5. GCC Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 8.6.1.6. South Africa Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 8.6.1.7. South Africa Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 8.6.1.8. South Africa Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 8.6.1.9. South Africa Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 8.6.1.10. South Africa Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 8.6.1.11. Egypt Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 8.6.1.12. Egypt Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 8.6.1.13. Egypt Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 8.6.1.14. Egypt Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 8.6.1.15. Egypt Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 8.6.1.16. Nigeria Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 8.6.1.17. Nigeria Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 8.6.1.18. Nigeria Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 8.6.1.19. Nigeria Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 8.6.1.20. Nigeria Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
  - 8.6.1.21. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
  - 8.6.1.22. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
  - 8.6.1.23. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
  - 8.6.1.24. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
  - 8.6.1.25. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
- 8.6.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Product vs Indication Heatmap
9.2. Company Market Share Analysis, 2024
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Pfizer Inc.
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Novartis AG
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Mylan N.V.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Teva Pharmaceuticals
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Merck & Co.
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Eli Lilly & Company
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. AstraZeneca PLC
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Lupin Limited
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Dr. Reddys Laboratories
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Aurobindo Pharma Ltd.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. GSK PLC
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development
- 9.4.12. Sun Pharmaceutical Industries Ltd.
  - 9.4.12.1. Company Overview
  - 9.4.12.2. Product Portfolio
  - 9.4.12.3. Financial Overview
  - 9.4.12.4. Business Strategies and Development
- 9.4.13. Cipla Ltd.
  - 9.4.13.1. Company Overview
  - 9.4.13.2. Product Portfolio
  - 9.4.13.3. Financial Overview
  - 9.4.13.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations